Fulcrum Therapeutics to Participate in Upcoming September Conferences
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming healthcare conferences in September 2024. The company, which focuses on developing small molecules for genetically defined rare diseases, will be attending:
1. The Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, in Boston, MA.
2. The Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York, NY.
During these events, Fulcrum's management team will engage in a series of investor meetings, providing an opportunity to discuss the company's progress and future plans in the field of rare disease treatments.
Fulcrum Therapeutics (Nasdaq: FULC), una azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a due imminenti conferenze sanitarie nel settembre 2024. L'azienda, che si concentra sullo sviluppo di piccole molecole per malattie rare definite geneticamente, parteciperà a:
1. Alla Wells Fargo Healthcare Conference mercoledì 4 settembre 2024, a Boston, MA.
2. Alla Morgan Stanley 22nd Annual Global Healthcare Conference venerdì 6 settembre 2024, a New York, NY.
Durante questi eventi, il team di gestione di Fulcrum parteciperà a una serie di incontri con investitori, offrendo l'opportunità di discutere i progressi e i piani futuri dell'azienda nel campo dei trattamenti per malattie rare.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en dos conferencias de salud que se llevarán a cabo en septiembre de 2024. La compañía, que se centra en el desarrollo de pequeñas moléculas para enfermedades raras definidas genéticamente, asistirá a:
1. La Wells Fargo Healthcare Conference el miércoles 4 de septiembre de 2024, en Boston, MA.
2. La Morgan Stanley 22nd Annual Global Healthcare Conference el viernes 6 de septiembre de 2024, en Nueva York, NY.
Durante estos eventos, el equipo de gestión de Fulcrum participará en una serie de reuniones con inversores, brindando una oportunidad para discutir el progreso y los planes futuros de la empresa en el ámbito de los tratamientos para enfermedades raras.
풀크럼 테라퓨틱스 (Nasdaq: FULC), 임상 단계의 생명공학 회사가 2024년 9월에 열리는 두 개의 보건 회의에 참석한다고 발표했습니다. 유전자적으로 정의된 희귀 질환을 위한 소분자 개발에 집중하는 이 회사는 다음 회의에 참석할 예정입니다:
1. 2024년 9월 4일 수요일, 보스턴 MA에서 열리는 웰스 파고 헬스케어 컨퍼런스.
2. 2024년 9월 6일 금요일, 뉴욕 NY에서 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스.
이 행사에서 풀크럼의 경영진은 투자자 회의를 진행하여 희귀 질환 치료 분야에서의 회사의 진행 상황 및 향후 계획을 논의할 기회를 제공할 것입니다.
Fulcrum Therapeutics (Nasdaq: FULC), une société bio-pharmaceutique en phase clinique, a annoncé sa participation à deux prochaines conférences de santé en septembre 2024. L'entreprise, qui se concentre sur le développement de petites molécules pour des maladies rares génétiquement définies, sera présente à :
1. La Wells Fargo Healthcare Conference le mercredi 4 septembre 2024, à Boston, MA.
2. La Morgan Stanley 22e Conférence Annuelle Mondiale sur la Santé le vendredi 6 septembre 2024, à New York, NY.
Au cours de ces événements, l'équipe de direction de Fulcrum participera à une série de réunions avec des investisseurs, offrant ainsi l'occasion de discuter des progrès et des projets futurs de l'entreprise dans le domaine des traitements des maladies rares.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Gesundheitskonferenzen im September 2024 angekündigt. Das Unternehmen, das sich auf die Entwicklung von kleinen Molekülen für genetisch definierte seltene Krankheiten konzentriert, wird an folgenden Veranstaltungen teilnehmen:
1. An der Wells Fargo Healthcare Conference am Mittwoch, den 4. September 2024, in Boston, MA.
2. An der Morgan Stanley 22nd Annual Global Healthcare Conference am Freitag, den 6. September 2024, in New York, NY.
Während dieser Veranstaltungen wird das Management-Team von Fulcrum eine Reihe von Investorenmeetings abhalten, um die Fortschritte und zukünftigen Pläne des Unternehmens im Bereich der Behandlungen für seltene Krankheiten zu erörtern.
- None.
- None.
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences:
- Wells Fargo Healthcare Conference
Wednesday, September 4, 2024
Boston, MA
- Morgan Stanley 22nd Annual Global Healthcare Conference
Friday, September 6, 2024
New York, NY
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
What conferences will Fulcrum Therapeutics (FULC) attend in September 2024?
What is Fulcrum Therapeutics' (FULC) focus in drug development?
Where is Fulcrum Therapeutics (FULC) based?
What stock exchange is Fulcrum Therapeutics (FULC) listed on?
What type of company is Fulcrum Therapeutics (FULC)?
